What humanin actually is, and why it was named for a hope

The peptide got its name before anyone knew what it did. In 2001 a group at Keio University was reading the brain of a patient who had died with Alzheimer's, looking for whatever had kept a small pocket of neurons alive while the tissue around them failed. They found a short sequence in the survivors that, when switched on in other cells, kept those cells from dying under the same genetic insult. The researchers called it humanin, for the humanity the disease takes and they hoped a molecule might give back. It was a lot to ask of twenty-four amino acids. Most of what makes it interesting is the gap between that name and what has actually been shown.

Where it comes from

Humanin is written inside the mitochondrial genome, in the stretch that codes for the 16S ribosomal RNA. For most of the last century the mitochondrial DNA was read as a closed list, a handful of genes for the energy machinery and nothing else. Humanin was the first evidence that the organelle was also quietly writing peptides of its own, a category we now call mitochondrial-derived peptides. MOTS-c, which this blog has covered, came fourteen years later from a neighboring gene. Humanin was the one that opened the drawer. A cell's power plant turning out to also send small signed notes was not in the textbook, and the discovery rewrote a page of it.

What it seems to do

In the dish, humanin behaves like a molecule whose job is to keep cells from quitting under stress. It blunted the toxicity of amyloid-beta, the fragment most associated with Alzheimer's, in the original experiments. Since then it has shown up protecting various cell types from various injuries: oxidative stress, the kind of damage that follows a blocked and then reopened blood vessel, the metabolic strain that comes with handling sugar poorly. Its level is not fixed. It falls with age, which is the pattern that pulls a molecule into longevity conversations whether or not it has earned the ticket.

There is also a thread connecting it to the body's growth signaling. In some long-lived animal strains, the ones that run low on growth hormone and its downstream messenger, humanin runs high. That inverse relationship is intriguing and badly understood, and it is exactly the kind of correlation that gets oversold.

What the evidence actually shows

Nearly all of the substance sits in cells and in animals, often using engineered analogs that are far more potent than the natural peptide. There the findings are real and repeatable. In people, the strongest evidence is observational: higher endogenous humanin has been associated with longer life, including in the children of centenarians, who inherit something that tracks with their parents' longevity. An association in humans and a set of effects in mice is a genuine reason to keep looking. It is not the same as a result.

What does not exist is the part that would matter to a person. There are no controlled trials establishing that giving humanin, or one of its analogs, does anything measurable in a human body, at what amount, with what safety profile, in whom. The mechanism has open questions at nearly every step, starting with how a peptide made inside the mitochondrion gets out and finds its targets. The honest summary is that humanin is a serious piece of biology with a thin clinical record, and the distance between those two is wide.

How to hold it

Hold it as a discovery, which is what it is, rather than a product. Humanin is the reason we now look at the mitochondrial genome and expect to find more than energy parts, and that shift is worth more than any single claim made for the peptide itself. The name was a hope expressed in 2001 by people watching a disease take everything. Hope is a fine thing to name a molecule for. It is a poor thing to dose yourself on. The science is early, the biology is real, and the two facts belong in the same sentence every time the peptide comes up.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.